DOCSLIB.ORG

NTP Annual Report 2012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NTP Annual Report 2012 National Toxicology Program U.S. Department of Health and Human Services Annual Report 2012 National Toxicology Program ANNUAL REPORT for Fiscal Year 2012 National Institute of Environmental Health Sciences National Institutes of Health National Center for Toxicological Research Food and Drug Administration National Institute for Occupational Safety and Health Centers for Disease Control and Prevention September 2013 Department of Health and Human Services National Toxicology Program NIH Publication No. 13-5970 Table of Contents Letter from the NIEHS/NTP Director ...................................................................................................... 1 1. National Toxicology Program: Mission And Goals ....................................................................... 3 A. Organizational Structure and Oversight ...................................................................................... 4 B. Training Programs ....................................................................................................................... 6 C. Advisory Boards and Committees ............................................................................................... 6 i. NTP Executive Committee .................................................................................................6 ii. NTP Board of Scientific Counselors ...................................................................................7 iii. Scientific Advisory Committee on Alternative Toxicological Methods .................................9 iv. Special Emphasis Panels .................................................................................................12 2. Funding ........................................................................................................................................... 14 3. NTP Highlighted Activities ............................................................................................................. 17 A. NIEHS Strategic Plan ................................................................................................................ 17 B. Systematic Review Process ...................................................................................................... 17 C. Health Effects of Low-Level Lead .............................................................................................. 18 D. Studies of Botanical Dietary Supplements ................................................................................ 18 E. Diversity-Outbred Mice and Population Based Models for Toxicology and Disease ................. 19 F. Mouse Methylome Project ......................................................................................................... 20 G. NTP Impact on Regulatory Agencies ......................................................................................... 20 H. Additional Activities .................................................................................................................... 22 4. Literature Analysis Activities ........................................................................................................ 23 A. Non-Cancer Health Effects ....................................................................................................... 23 B. Report on Carcinogens .............................................................................................................. 24 5. Testing and Research .................................................................................................................... 26 A. Technical Reports ...................................................................................................................... 27 B. NTP Testing ............................................................................................................................... 32 i. Disposition, Metabolism, and Toxicokinetic Studies .........................................................33 ii. Genetic Toxicity ................................................................................................................34 iii. Organ System Toxicity ......................................................................................................35 iv. Toxicology/Carcinogenicity Studies ..................................................................................41 v. Toxicogenomic Studies .....................................................................................................46 C. NTP Research ........................................................................................................................... 48 i. Assessing Exposure to Substances in the Workplace .....................................................51 ii. Comprehensive Assessment of Occupationally-Relevant Exposures ..............................55 iii. Immunotoxicology Research ............................................................................................56 iv. NTP Research in Partnership with NCTR ........................................................................59 6. Alternative Methods Development ................................................................................................ 70 A. Tox 21 ........................................................................................................................................ 70 B. ICCVAM ..................................................................................................................................... 74 i. Workshops ........................................................................................................................74 ii. Publications ......................................................................................................................75 iii. International Validation Activities ......................................................................................76 7. Public Tools .................................................................................................................................... 78 A. Chemical Effects in Biological Systems (CEBS) Database ....................................................... 78 B. NTP Archives ............................................................................................................................. 78 C. The NCGC BioPlanet ................................................................................................................ 79 D. DrugMatrix® and ToxFX® .......................................................................................................... 79 E. MetaDataViewer ........................................................................................................................ 80 8. Appendices ..................................................................................................................................... 81 A. Frequently Used Abbreviations .................................................................................................. 81 B. Agency Staff and Contact Information ....................................................................................... 83 C. FY 2012 Bibliography ................................................................................................................ 87 Letter from the NIEHS/NTP Director The NTP, an interagency program, provides scientific knowledge and functions as a truly translational program to safeguard public health. The NTP is involved in activities to evaluate substances of potential concern for our health and to develop new methods to improve such evaluation procedures. For example, the NTP is taking on the challenge of studying mixtures instead of testing one chemical at a time. In addition, a current project is examining the effects of exposures throughout a life span, to expand our knowledge about effects of prenatal exposures and how they may link to adult disease. The NTP is also leading the Tox21 initiative with the National Institutes of Health’s National Center for Advancing Translational Science, the United States Environmental Protection Agency, and the Food and Drug Administration. Tox21 is a high throughput-testing program that shows great promise for moving toxicology into a predictive science. As it has done in the past, in fiscal year 2012 (FY 2012), the NTP through scientific collaborations with federal agencies continued to enhance our knowledge about substances that affect health in our homes, workplaces, and other environments. The NTP translated and communicated these findings to the public, industry, federal regulatory agencies, and others so the information could be used to protect public health. The NTP disseminated reports on studies of dietary supplements, skin care products, and widely used industrial chemicals through publication of nine NTP Technical Reports. The final NTP Monograph on Heath Effects of Low-level Lead was published, providing an overview of the science to date and conclusions on the potential health effects from low-level exposures to lead. The NTP also carried out two widely attended workshops: (1) the International Workshop on Alternative Methods for Human and Veterinary Rabies Vaccine Testing: State of the Science and Planning the Way Forward and (2) the International Workshop on Alternative Methods for Leptospira Vaccine Potency Testing: State of the Science and the Way Forward. Of broad interest both nationally and internationally, the NIEHS Office of Health Assessment and Translation initiated modifications in how
Load more

Recommended publications
  • Retention Indices for Frequently Reported Compounds of Plant Essential Oils
    Retention Indices for Frequently Reported Compounds of Plant Essential Oils V. I. Babushok,a) P. J. Linstrom, and I. G. Zenkevichb) National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA (Received 1 August 2011; accepted 27 September 2011; published online 29 November 2011) Gas chromatographic retention indices were evaluated for 505 frequently reported plant essential oil components using a large retention index database. Retention data are presented for three types of commonly used stationary phases: dimethyl silicone (nonpolar), dimethyl sili- cone with 5% phenyl groups (slightly polar), and polyethylene glycol (polar) stationary phases. The evaluations are based on the treatment of multiple measurements with the number of data records ranging from about 5 to 800 per compound. Data analysis was limited to temperature programmed conditions. The data reported include the average and median values of retention index with standard deviations and confidence intervals. VC 2011 by the U.S. Secretary of Commerce on behalf of the United States. All rights reserved. [doi:10.1063/1.3653552] Key words: essential oils; gas chromatography; Kova´ts indices; linear indices; retention indices; identification; flavor; olfaction. CONTENTS 1. Introduction The practical applications of plant essential oils are very 1. Introduction................................ 1 diverse. They are used for the production of food, drugs, per- fumes, aromatherapy, and many other applications.1–4 The 2. Retention Indices ........................... 2 need for identification of essential oil components ranges 3. Retention Data Presentation and Discussion . 2 from product quality control to basic research. The identifi- 4. Summary.................................. 45 cation of unknown compounds remains a complex problem, in spite of great progress made in analytical techniques over 5.
    [Show full text]
  • Picrotoxin-Like Channel Blockers of GABAA Receptors
    COMMENTARY Picrotoxin-like channel blockers of GABAA receptors Richard W. Olsen* Department of Molecular and Medical Pharmacology, Geffen School of Medicine, University of California, Los Angeles, CA 90095-1735 icrotoxin (PTX) is the prototypic vous system. Instead of an acetylcholine antagonist of GABAA receptors (ACh) target, the cage convulsants are (GABARs), the primary media- noncompetitive GABAR antagonists act- tors of inhibitory neurotransmis- ing at the PTX site: they inhibit GABAR Psion (rapid and tonic) in the nervous currents and synapses in mammalian neu- system. Picrotoxinin (Fig. 1A), the active rons and inhibit [3H]dihydropicrotoxinin ingredient in this plant convulsant, struc- binding to GABAR sites in brain mem- turally does not resemble GABA, a sim- branes (7, 9). A potent example, t-butyl ple, small amino acid, but it is a polycylic bicyclophosphorothionate, is a major re- compound with no nitrogen atom. The search tool used to assay GABARs by compound somehow prevents ion flow radio-ligand binding (10). through the chloride channel activated by This drug target appears to be the site GABA in the GABAR, a member of the of action of the experimental convulsant cys-loop, ligand-gated ion channel super- pentylenetetrazol (1, 4) and numerous family. Unlike the competitive GABAR polychlorinated hydrocarbon insecticides, antagonist bicuculline, PTX is clearly a including dieldrin, lindane, and fipronil, noncompetitive antagonist (NCA), acting compounds that have been applied in not at the GABA recognition site but per- huge amounts to the environment with haps within the ion channel. Thus PTX major agricultural economic impact (2). ͞ appears to be an excellent example of al- Some of the other potent toxicants insec- losteric modulation, which is extremely ticides were also radiolabeled and used to important in protein function in general characterize receptor action, allowing and especially for GABAR (1).
    [Show full text]
  • Erowid Extracts — Number 13 / November 2007 Erowid Extracts Table of Contents Number 13, November 2007
    Erowid® Extracts D OCUMENTING THE C OMPLEX R ELATIONSHIP B ETWEEN H UMANS AN D P SYCHOACTIVES November 2007 Number 13 “The problem to be faced is: how to combine loyalty to one’s own tradition with reverence for different traditions.” — Abraham J. Heschel The Absinthe Enigma • Wormwood and Thujone • P. viridis vs. M. tenuiflora Varieties of Nicotine Experience • Khat Legal Challenges LETTERS & FEEDBACK Hi there Erowid staff, First of all, thank you for such Awesome website! A more thoughtfully a wonderful site. I’m not a serious compiled compendium of information I’m just writing to say how much I recreational user, but having some on the topic of psychoactives does appreciate your website. My father chronic pain issues, I tend to experiment not exist—at least not for the public showed it to me several years ago a little to find ways to alleviate the at large. Bravo. and it’s been fun to watch it grow pain (aside from standard Rx’s from in quality and content over the — ANOnymOus doctors). […] years. My dad adjunctly teaches a Letter to Erowid psychopharmacology class in town and Keep up the good work. Although always lists Erowid on his syllabus of some might look at Erowid negatively, recommended readings. I’m a college I look at it positively, in the sense that After looking up information on the student and am surprised, once I I’m smart enough to research things antitussive properties of DXM, how start talking to other kids, how many before I try them, and hopefully keep shocked I was to find your website, of them know about the information myself from an early demise.
    [Show full text]
  • Assessment Report on Salvia Officinalis L., Folium and Salvia Officinalis L., Aetheroleum Final
    20 September 2016 EMA/HMPC/150801/2015 Committee on Herbal Medicinal Products (HMPC) Assessment report on Salvia officinalis L., folium and Salvia officinalis L., aetheroleum Final Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC (traditional use) Herbal substance(s) (binomial scientific name of Salvia officinalis L., folium and the plant, including plant part) Salvia officinalis L., aetheroleum Herbal preparation(s) a) Comminuted herbal substance b) Liquid extract (DER 1:1), extraction solvent ethanol 70% V/V c) Dry extract (DER 4-7:1), extraction solvent water d) Liquid extract (DER 1:3.5-5), extraction solvent ethanol 31.5% V/V e) Liquid extract (DER 1:4-5) extraction solvent ethanol 50% V/V f) Liquid extract (DER 1:4-6), extraction solvent liquor wine:ethanol 96% V/V (38.25:61.75 m/m) g) Tincture (ratio of herbal substance to extraction solvent 1:10) extraction solvent ethanol 70% V/V Pharmaceutical form(s) Comminuted herbal substance as herbal tea for oral use. Comminuted herbal substance for infusion preparation for oromucosal or cutaneous use. Herbal preparations in solid or liquid dosage forms for oral use. Herbal preparations in liquid or semi-solid dosage forms for cutaneous use or for oromucosal use. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.
    [Show full text]
  • Plant-Based Medicines for Anxiety Disorders, Part 2: a Review of Clinical Studies with Supporting Preclinical Evidence
    CNS Drugs 2013; 24 (5) Review Article Running Header: Plant-Based Anxiolytic Psychopharmacology Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence Jerome Sarris,1,2 Erica McIntyre3 and David A. Camfield2 1 Department of Psychiatry, Faculty of Medicine, University of Melbourne, Richmond, VIC, Australia 2 The Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia 3 School of Psychology, Charles Sturt University, Wagga Wagga, NSW, Australia Correspondence: Jerome Sarris, Department of Psychiatry and The Melbourne Clinic, University of Melbourne, 2 Salisbury Street, Richmond, VIC 3121, Australia. Email: [email protected], Acknowledgements Dr Jerome Sarris is funded by an Australian National Health & Medical Research Council fellowship (NHMRC funding ID 628875), in a strategic partnership with The University of Melbourne, The Centre for Human Psychopharmacology at the Swinburne University of Technology. Jerome Sarris, Erica McIntyre and David A. Camfield have no conflicts of interest that are directly relevant to the content of this article. 1 Abstract Research in the area of herbal psychopharmacology has revealed a variety of promising medicines that may provide benefit in the treatment of general anxiety and specific anxiety disorders. However, a comprehensive review of plant-based anxiolytics has been absent to date. Thus, our aim was to provide a comprehensive narrative review of plant-based medicines that have clinical and/or preclinical evidence of anxiolytic activity. We present the article in two parts. In part one, we reviewed herbal medicines for which only preclinical investigations for anxiolytic activity have been performed. In this current article (part two), we review herbal medicines for which there have been both preclinical and clinical investigations for anxiolytic activity.
    [Show full text]
  • Variability of Thujone Content in Essential Oil Due to Plant Development and Organs from Artemisia Absinthium L
    Journal of Applied Botany and Food Quality 92, 100 - 105 (2019), DOI:10.5073/JABFQ.2019.092.014 Department of Medicinal and Aromatic Plants, Szent István University, Budapest, Hungary Variability of thujone content in essential oil due to plant development and organs from Artemisia absinthium L. and Salvia officinalis L. Huong Thi Nguyen*, Péter Radácsi, Péter Rajhárt, Éva Zámboriné Németh (Submitted: March 4, 2019; Accepted: March 22, 2019) Summary 5.0 mg thujone/day/person for a maximum duration of use of 2 weeks (EMA/HMPC, 2008b). The study compared changes in essential oil content and its thujone Although both α- and β-thujones are also found naturally in con- ratio in two popular herbs (Artemisia absinthium L. and Salvia offi- siderable concentrations in other essential oils (EO) such as tansy cinalis L.), pertaining to plant development and plant organs. Both (Tanacetum vulgare), white-cedar (Thuja occidentalis), and other species were harvested in 2018 at the vegetative, floral budding, Artemisia and Achillea species (PELKONEN et al., 2013), the above flowering and after flowering phases; flowers and leaves were sam- mentioned A. absinthium and S. officinalis species are the most cha- pled separately. The essential content is always higher in the flowers racteristic ones as well as being found in numerous preparations fre- than in the leaves at the same phenophase in both species we exa- quently used by consumers. mined. Decreased essential oil content in both organs during the The mean concentration of α- and β-thujones in A. absinthium oils developmental phases was also common to both species. In S.
    [Show full text]
  • Sage, Skullcap, and Castor Oil
    Sage, Skullcap, and Castor Oil “In this conversation on herbal medicine I want to briefly cover my use of three herbs, Sage, Skullcap, and Castor Oil. I have used these herbs in combination in the treatment of diabetic neuropathy, and in the example of the case history to follow, to save a patient’s leg scheduled for amputation. Several years ago, an elderly man came to see me professionally. He had been a carpenter all his life and now 83 years old he was building homes through Habitat for Humanity. Specifically, he was working to rebuild homes destroyed by hurricane Katrina. He came to see me on the recommendation of another patient and because he was scheduled to have his right leg amputated. The amputation was deemed medically necessary because of damage to a major artery in his leg as the result of a previous vascular surgery. He and his doctors were concerned that he would not survive the surgery, but his main concern was that he would no longer be able to serve people through his Christian mission of rebuilding their damaged homes. His surgery was scheduled in six weeks (he was delaying it as long as possible) and his request of me was to save his leg. His leg was a mess. From just above the knee to his toes his leg was a tobacco brown color (he was a caucasian male). In addition to the extreme discoloration his skin was hardened like plastic. The tissue in the leg appeared to be dead, it had no softness to it.
    [Show full text]
  • Roth 04 Pharmther Plant Derived Psychoactive Compounds.Pdf
    Pharmacology & Therapeutics 102 (2004) 99–110 www.elsevier.com/locate/pharmthera Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery Bryan L. Rotha,b,c,d,*, Estela Lopezd, Scott Beischeld, Richard B. Westkaempere, Jon M. Evansd aDepartment of Biochemistry, Case Western Reserve University Medical School, Cleveland, OH, USA bDepartment of Neurosciences, Case Western Reserve University Medical School, Cleveland, OH, USA cDepartment of Psychiatry, Case Western Reserve University Medical School, Cleveland, OH, USA dNational Institute of Mental Health Psychoactive Drug Screening Program, Case Western Reserve University Medical School, Cleveland, OH, USA eDepartment of Medicinal Chemistry, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA Abstract Because psychoactive plants exert profound effects on human perception, emotion, and cognition, discovering the molecular mechanisms responsible for psychoactive plant actions will likely yield insights into the molecular underpinnings of human consciousness. Additionally, it is likely that elucidation of the molecular targets responsible for psychoactive drug actions will yield validated targets for CNS drug discovery. This review article focuses on an unbiased, discovery-based approach aimed at uncovering the molecular targets responsible for psychoactive drug actions wherein the main active ingredients of psychoactive plants are screened at the ‘‘receptorome’’ (that portion of the proteome encoding receptors). An overview of the receptorome is given and various in silico, public-domain resources are described. Newly developed tools for the in silico mining of data derived from the National Institute of Mental Health Psychoactive Drug Screening Program’s (NIMH-PDSP) Ki Database (Ki DB) are described in detail.
    [Show full text]
  • Lipid Peroxidation Inhibition, Superoxide Anion and Nitric Oxide Radical Scavenging Properties of Thymus Daenensis and Anethum Graveolens Essential Oils
    Journal of Medicinal Plants Lipid Peroxidation Inhibition, Superoxide Anion and Nitric Oxide Radical Scavenging Properties of Thymus daenensis and Anethum graveolens Essential Oils Dadashpour M (M.Sc. student)1, Rasooli I (Ph.D.)2*, Sefidkon F (Ph.D.)3, Rezaei MB (Ph.D.)3, Darvish Alipour Astaneh S (Ph.D. student)4 1- Department of Biotechnology, College of Basic Sciences, Shahed University, Tehran, Iran 2- Medicinal Plants Research Center and Department of Biology, Shahed University, Tehran, Iran 3- Department of Medicinal Plants, Research Institute of Forests and Rangelands, Tehran, Iran 4- Department of Microbiology, College of Basic Sciences, Shahed University, Tehran-Iran *Corresponding author: Department of Biology, College of Basic Sciences, Shahed University, Tehran-Iran Email: [email protected] Receive: 4 Dec. 2010 Acceptance: 1 Feb. 2011 Abstract Background: Safety and efficacy of the synthetic antioxidants used in the food industry are frequently questioned because such antioxidants are unstable and highly volatile, therefore, interest in finding naturally occurring antioxidants that have the potential to protect human beings from damage induced by oxidative stress has intensified. Objective: Bioactivities of Thymus daenensis and Anethum graveolens essential oils with special reference to their antioxidative properties are studied. Downloaded from jmp.ir at 19:29 +0330 on Tuesday September 28th 2021 Methods: Total phenolic content (TPC), lipid peroxidation inhibition (LPI), ferrous-ion chelating (FIC), superoxide anion and nitric oxide radical scavenging, and tyrosinase inhibition activities of the essential oils were determined. Results: TPC of T. daenensis and A. graveolens oils were 644.07±6.79 and 174.91±2.05 mg GAE/100 g.
    [Show full text]
  • Study of Plants Used Against Infections by California Native
    STUDY OF PLANTS USED AGAINST INFECTIONS BY CALIFORNIA NATIVE AMERICAN TRIBES A Thesis presented to the Faculty of California Polytechnic State University, San Luis Obispo In Partial Fulfillment of the Requirements for the Degree Master of Science in Biological Sciences by Maria Rojas December 2020 © 2020 Maria Jose Rojas Soto ALL RIGHTS RESERVED ii COMMITTEE MEMBERSHIP TITLE: Study of Plants Used Against Infections by California Native American Tribes AUTHOR: Maria Jose Rojas Soto DATE SUBMITTED: December 2020 COMMITTEE CHAIR: Alejandra Yep, Ph.D. Associate Professor Biological Sciences Department COMMITTEE MEMBER: Jenn Yost, Ph.D. Associate Professor Biological Sciences Department COMMITTEE MEMBER: Jennifer Carroll, Ph.D. Professor Chemistry & Biochemistry Department iii ABSTRACT Study of Plants Used Against Infections by California Native American Tribes Maria Jose Rojas Soto The objectives of this research were to evaluate the antibacterial activity and to determine the chemical composition of a list of medicinal plants used by Native Americans in California. Artemisia californica, Mimulus aurantiacus, Equisetum telmateia, Equisetum hyemale, and Marah fabacea were selected from a list of plants reported as having been used for ailments related to infections by tribes located in California. The extracts obtained through steam distillation from E. telmateia, E. hyemale and M. fabacea were assayed for in vitro antibacterial activity against 16 Gram-negative and 6 Gram-positive bacteria using disk diffusion assays and measuring the diameters of inhibition zones. E. telmateia showed the most promising antibacterial activity. The extracts from A. californica, M. aurantiacus and E. telmateia were analyZed for chemical composition, finding eucalyptol, thujone, eugenol, caryophyllene, germacrene D, and propanal as some of the secondary metabolites identified using GC-MS.
    [Show full text]
  • Essential Oil Composition and Anti-Inflammatory Activity of Salvia Officinalis L (Lamiaceae) in Murin Macrophages
    Tosun et al Tropical Journal of Pharmaceutical Research June 2014; 13 (6): 937-942 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v13i6.16 Original Research Article Essential Oil Composition and Anti-Inflammatory Activity of Salvia officinalis L (Lamiaceae) in Murin Macrophages Alev Tosun1*, Salman Khan2, Yeong Shik Kim2, Ángel Calín-Sánchez3, Xhevit Hysenaj4 and Ángel Antonio Carbonell-Barrachina3 1Ankara University, Faculty of Pharmacy, Department of Pharmacognosy, 06100, Tandoğan, Ankara, Turkey, 2Natural Product Research Institute, College of Pharmacy, Seoul National University, Seoul, 151-742, South Korea, 3Departamento Tecnología Agroalimentaria, Universidad Miguel Hernández de Elche, Carretera de Beniel, 03312 Orihuela, Alicante, Spain, 4Xherdo Ltd., Medicinal Plants and Essential Oils, Nikolla Lena, No.138, Tirana, Albania *For correspondence: Email: [email protected]; Tel: +90 312 203 30 89; Fax: +90 312 213 10 81 Received: 13 May 2013 Revised accepted: 2 April 2014 Abstract Purpose: Sage, Salvia officinalis L (Lamiaceae), is widely cultivated medicinal plant for its economic importance and large content of bioactive components; therefore, in the present study, the active components (volatile compounds) and the anti-inflammatory effect of S. officinalis have been investigated. Methods: Salvia officinalis samples were collected from northern
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,636,316 B2 Cohen Et Al
    USOO9636316B2 (12) United States Patent (10) Patent No.: US 9,636,316 B2 Cohen et al. (45) Date of Patent: May 2, 2017 (54) BACLOFENAND ACAMPROSATE BASED (58) Field of Classification Search THERAPY OF NEUROLOGICAL DISORDERS CPC ... A61K 31/197; A61K 31/445; A61K 31/42: A61K 31/44; A61K 31/195; A61 K (71) Applicant: PHARNEXT, Issy les Moulineaux (FR) 31/185; A61K 31/138: A61K 31/164 (72) Inventors: Daniel Cohen, Saint Cloud (FR); Ilya USPC ................................. 514/567, 555, 568, 665 Chumakov, Vaux-le-Penil (FR); See application file for complete search history. Serguei Nabirochkin, Chatenay-Malabry (FR); Emmanuel Vial, Paris (FR); Mickael Guedj. Paris (56) References Cited (FR) U.S. PATENT DOCUMENTS (73) Assignee: PHARNEXT, Issy les Moulineaux (FR) 6,391922 B1 5/2002 Fogel 8,741,886 B2 6, 2014 Cohen et al. Notice: Subject to any disclaimer, the term of this 2001, 0004640 A1 6/2001 Inada et al. (*) 2001 OO23246 A1 9, 2001 Barritault et al. patent is extended or adjusted under 35 2004.0102525 A1 5, 2004 KOZachuk U.S.C. 154(b) by 0 days. 2008. O18851.0 A1 8, 2008 Yoshino 2009 OO69419 A1 3/2009 Jandeleit et al. (21) Appl. No.: 14/861,169 2009/O197958 A1 8/2009 Sastry et al. 2011 O230659 A1 9/2011 Tsukamoto et al. (22) Filed: Sep. 22, 2015 2012fO27083.6 A1 10, 2012 Cohen et al. (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2016/OOOO736A1 Jan. 7, 2016 EP 1 S63 846 8, 2005 EP 1837 O34 9, 2007 WO WO O1, 58.476 8, 2001 WO WO O3,OOT993 1, 2003 Related U.S.
    [Show full text]